Bone Loss Completed Phase 3 Trials for Zoledronic acid (DB00399)

Also known as: Osteopenia / Osteopaenia

IndicationStatusPhase
DBCOND0031952 (Bone Loss)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00171340Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.Treatment